Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|May 1, 2024
The 10 States with the Largest ↑ Increase in Diabetes Dx & 5 States with the Largest ↓ Decrease
Author(s)Grace Halsey
Diagnoses of diabetes increased the most in South Dakota between 2018 and 2021 at 18.45%; diagnoses decreased the most in Hawaii at 15.61%. More, here.
Advertisement
Diabetes awareness website Diabetes Strong analyzed data from the US Centers for Disease Control and Prevention, comparing the number of adults diagnosed with diabetes in each state in 2018 and in 2021 (the latter is the most recent data set). The comparisons create a topline look at the current prevalence of diabetes in the US.
Spoiler: South Dakota tops the list of states with a double-digit increase over the 3 years (18.45%) and Hawaii saw the greatest decreases in diabetes diagnoses over the same period (15.61%), according to the results.
Liitations to the data: No differentiation is made between types of diabetes so there is no way to know which type/s are increasing/decreasing most; also, only adults aged 18 years and older were included so type 1 diabetes diagnoses are likely underrepresented, the majority of those being made before age 18.
Source: Oerum C. Diabetes rates rise in most (but not all) US states. Diabetes Strong. Updated April 30, 2024. Accessed April 30, 2024. https://diabetesstrong.com/diabetes-rates-by-us-state/
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement